SAN DIEGO, Jan. 8, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
offerings designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that it has been awarded U.S. Patent No.
10,527,611 titled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS
from the United States Patent and Trademarks Office (USPTO). The
newly issued patent covers devices for the detection of cells of
interest, including circulating tumor cells (CTCs), that are shed
into the bloodstream by solid tumors where an antibody, or mixture
of antibodies, and any solid surface are used for cell capture,
detection, and analysis. This patent includes any biological sample
type of interest and includes the use of single antibodies or
cocktails of antibodies.
"The granting of this patent broadly expands Biocept's
intellectual property estate for capturing and detecting cells of
interest using antibodies, which combines nicely with our patented
microchannel and cell staining platforms," said Lyle Arnold, Ph.D., Biocept's Chief Scientific
Officer. "This allowed patent also interfaces very well with our
other patented technologies that include a blood collect tube, and
ctDNA analysis platforms for aiding patient treatment
decisions."
The device claims covered by this issued patent broadly cover
the use of antibodies for the capture and detection of target cells
of interest on any solid surface. This includes CTCs, as well as
any other cell of interest. Combined with the company's patented
microchannel and cell staining platform technologies, Biocept now
has patented the capability to enable the capture of any cell of
interest, including very rare cells, that may be present in blood
and any other biological sample type.
Michael Nall, Biocept's President
and CEO, added, "We continue to lead the way in innovation for
liquid biopsy technology, and this latest patent demonstrates our
leadership in creating new methodologies to identify potential
cancer cells, or cells of any type for that matter. We are
very proud of our innovations in the industry and look forward to
sharing future applications for this patented technology to capture
cellular targets in biological fluids, even when found in very
small quantities."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer. The Company's patented Target Selector™
liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to future applications of our
technologies, and the ability of our tests to provide clinically
actionable information to oncologist and their patients, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at sec.gov.
CONTACTS
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
Media Contact:
CORE IR
Jules Abraham
julesa@coreir.com
917-885-7378
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-inc-awarded-united-states-patent-for-the-use-of-antibodies-in-combination-with-any-solid-surface-to-detect-any-target-cell-of-interest---from-any-sample-type-300983356.html
SOURCE Biocept, Inc.